TRIM21‐Mediated K11‐Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202502501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, the Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang, Hebei, 050011, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Inhibitor of Differentiation Protein 1, Esophageal Neoplasms, Ribonucleoproteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hebei Natural Science Foundation, Postdoctoral Fellowship Program of CPSF.
Abstract (Originalsprache)
Inhibitor of DNA binding 1 (ID1) is a key transcriptional regulator involved in the development of various cancers, including esophageal squamous cell carcinoma (ESCC). However, the mechanisms regulating ID1 ubiquitination in ESCC are not well understood. This study identifies TRIM21 as a novel E3 ubiquitin ligase that targets ID1 for K11‐linked ubiquitination at lysine 91. Unlike typical ubiquitination that marks proteins for degradation, TRIM21‐mediated K11 ubiquitination does not affect ID1 stability. Instead, it disrupts the ID1‐TCF12 interaction, releasing TCF12 to activate SLC31A1, a copper transporter. Elevated SLC31A1 expression increases intracellular copper, inducing cuproptosis and inhibiting ESCC cell proliferation and tumor growth. Functional assays show that overexpressing TRIM21 suppresses ESCC progression, while TRIM21 knockdown promotes growth. Clinically, low TRIM21 expression correlates with advanced disease stage and poorer patient survival rate, underscoring its prognostic value. Additionally, Sorafenib treatment upregulates TRIM21, enhancing ID1 ubiquitination, increasing SLC31A1 expression, and inducing cuproptosis. These findings uncover the TRIM21‐ID1‐TCF12‐SLC31A1 axis as a critical pathway in ESCC progression, suggesting that targeting this axis with Sorafenib can offer a promising therapeutic strategy for inhibiting tumor growth and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center, the Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang, Hebei, 050011, China.
- Hebei Medical University Clinical Medicine Postdoctoral Research Station, Jiankang Road 12, Shijiazhuang, Hebei, 050011, China.
- Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
ORCID-Profile: Lianmei Zhao
Förderung
- National Natural Science Foundation of China
- Hebei Natural Science Foundation
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- Medical Science Research Project of Hebei
- Hebei Medical University Postdoctoral Fund
Zitieren
APA
Li, L., Wang, Y., Tian, R., Yang, T., Liu, Y., Shan, B., & Zhao, L. (2025). TRIM21‐Mediated K11‐Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202502501
Vancouver
Li L, Wang Y, Tian R, Yang T, Liu Y, Shan B, et al. TRIM21‐Mediated K11‐Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202502501
BibTeX
@article{Li2025,
author = {Li, Lei and Wang, Yuqing and Tian, Ruoxi and Yang, Tianshuo and Liu, Yaxin and Shan, Baoen and Zhao, Lianmei},
title = {TRIM21‐Mediated K11‐Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502501}
}
EUVIMED